Metformin improves survival in patients with concurrent diabetes and small cell lung cancer: a meta-analysis.

IF 2.5 Q3 ENDOCRINOLOGY & METABOLISM

Minerva endocrinology Pub Date : 2023-06-01 DOI:10.23736/S2724-6507.21.03289-2

Hua Fan, Shikun Bai, Xin Guan, Wen Ma, Yu Fu, Xuan Zhang, Lili Deng, Jing Tian

{"title":"Metformin improves survival in patients with concurrent diabetes and small cell lung cancer: a meta-analysis.","authors":"Hua Fan, Shikun Bai, Xin Guan, Wen Ma, Yu Fu, Xuan Zhang, Lili Deng, Jing Tian","doi":"10.23736/S2724-6507.21.03289-2","DOIUrl":null,"url":null,"abstract":"Introduction: To compare survival outcome among the patients with concurrent small cell lung cancer (SCLC) and diabetes mellitus (DM) using metformin or without metformin.Evidence acquisition: A systematic literature search for relevant studies up to Oct 2020 was conducted. Outcome of the included studies included overall survival (OS) or disease-free survival (DFS). HR values were pooled to estimate the effect of metformin on survival outcomes.Evidence synthesis: Six studies with 539 participants with both SCLC and diabetes were included in the analysis. The patients with metformin usage had significantly longer OS and DFS than those without metformin usage (OS: HR=0.72 [0.53-0.98], P=0.04; DFS: HR=0.59 [0.45-0.76], P<0.0001). The studies included were not significantly different in the two analyses by heterogeneity test. There was no obvious publication bias.Conclusions: Metformin may improve survival among patients with concurrent SCLC and DM. Further investigations especially randomized control trials are warranted, especially among the patients who do not have diabetes.","PeriodicalId":18690,"journal":{"name":"Minerva endocrinology","volume":null,"pages":null},"PeriodicalIF":2.5000,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Minerva endocrinology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.23736/S2724-6507.21.03289-2","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 1

Abstract

Introduction: To compare survival outcome among the patients with concurrent small cell lung cancer (SCLC) and diabetes mellitus (DM) using metformin or without metformin.

Evidence acquisition: A systematic literature search for relevant studies up to Oct 2020 was conducted. Outcome of the included studies included overall survival (OS) or disease-free survival (DFS). HR values were pooled to estimate the effect of metformin on survival outcomes.

Evidence synthesis: Six studies with 539 participants with both SCLC and diabetes were included in the analysis. The patients with metformin usage had significantly longer OS and DFS than those without metformin usage (OS: HR=0.72 [0.53-0.98], P=0.04; DFS: HR=0.59 [0.45-0.76], P<0.0001). The studies included were not significantly different in the two analyses by heterogeneity test. There was no obvious publication bias.

Conclusions: Metformin may improve survival among patients with concurrent SCLC and DM. Further investigations especially randomized control trials are warranted, especially among the patients who do not have diabetes.

查看原文本刊更多论文

二甲双胍提高糖尿病合并小细胞肺癌患者的生存率:一项荟萃分析

前言:比较合并小细胞肺癌(SCLC)和糖尿病(DM)患者使用或不使用二甲双胍的生存结局。证据获取:系统检索截至2020年10月的相关研究文献。纳入研究的结果包括总生存期(OS)或无病生存期(DFS)。合并HR值来估计二甲双胍对生存结果的影响。证据综合:6项研究，539名同时患有SCLC和糖尿病的参与者被纳入分析。使用二甲双胍的患者的OS和DFS明显长于未使用二甲双胍的患者(OS: HR=0.72 [0.53-0.98]， P=0.04;DFS: HR=0.59 [0.45-0.76]， p结论:二甲双胍可以提高并发SCLC和DM患者的生存率。进一步的研究特别是随机对照试验是有必要的，特别是在没有糖尿病的患者中。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Minerva endocrinology

CiteScore

4.60

自引率

0.00%

发文量

146